What happens to the vaginal pH in atrophic vaginitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

In atrophic vaginitis, the vaginal pH increases above the normal range of 3.8-4.5, typically rising to 5.0-7.0, as a result of estrogen deficiency leading to thinning of the vaginal epithelium and reduced glycogen content in vaginal cells. This elevation occurs because the decreased glycogen availability leads to decreased colonization by Lactobacillus bacteria, which normally produce lactic acid that maintains the acidic vaginal environment 1. The resulting higher pH creates a more alkaline environment that favors the growth of pathogenic bacteria, contributing to symptoms such as vaginal dryness, burning, itching, and discomfort.

Key Factors Contributing to pH Change

  • Estrogen deficiency
  • Thinning of the vaginal epithelium
  • Reduced glycogen content in vaginal cells
  • Decreased colonization by Lactobacillus bacteria

Diagnostic and Therapeutic Implications

The pH change is a key diagnostic feature of atrophic vaginitis and helps distinguish it from other vaginal conditions. Treatment typically involves local or systemic estrogen therapy to restore the vaginal epithelium, increase glycogen production, and subsequently normalize the vaginal pH by promoting the return of Lactobacillus colonization 1. According to the most recent guidelines, vaginal estrogen is the most effective treatment for vaginal dryness leading to sexual dysfunction and has been shown to be effective in treating itching, discomfort, and painful intercourse in postmenopausal individuals 1.

Recent Guidelines and Recommendations

Recent studies, such as the NCCN guidelines, suggest that vaginal estrogen can be safely used in survivors of hormone receptor-positive breast cancer receiving aromatase inhibitor therapy, with no evidence of increased risk of breast cancer-specific mortality 1. However, the safety of vaginal hormones has not been firmly established in survivors of estrogen-dependent cancers, and their use should be approached with caution. The use of vaginal estrogen, such as an estradiol-releasing vaginal ring, is recommended as a first-line treatment for atrophic vaginitis, given its efficacy in restoring the vaginal epithelium and normalizing the vaginal pH.

From the Research

Vaginal pH in Atrophic Vaginitis

  • The vaginal pH in atrophic vaginitis is increased due to estrogen deficiency 2, 3.
  • This increase in vaginal pH predisposes the vagina and urinary tract to infection and mechanical weakness 2.
  • The increased vaginal pH is a result of the thinned endometrium and decreased levels of estrogen 2.
  • The testing of the vaginal pH can serve as a surrogate for evaluating urethral pH and as a monitor of compliance with treatment 3.
  • Locally applied vaginal conjugated estrogen cream can normalize the pH in the vagina and urethra 3.

Symptoms and Treatment

  • Atrophic vaginitis is associated with symptoms such as vaginal dryness, dyspareunia, and recurrent urinary tract infections 4, 5.
  • Treatment usually depends on estrogen replacement, which can be provided systemically or locally 2.
  • Vaginal moisturizers and lubricants, and participation in coitus may also be beneficial in the treatment of women with atrophic vaginitis 2, 4.
  • Topical estrogen replacement therapies can reverse mucosal changes and are effective treatments for the symptoms of atrophic vaginitis 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Diagnosis and treatment of atrophic vaginitis.

American family physician, 2000

Research

Atrophic vaginitis.

Dermatologic therapy, 2010

Research

Lactational atrophic vaginitis.

Journal of midwifery & women's health, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.